Mereo BioPharma (MREO) Other Non-Current Assets (2023 - 2026)

Mereo BioPharma (MREO) has reported Other Non-Current Assets for 4 consecutive years, with $387000.0 the latest figure, recorded in Q1 2026.

• Quarterly Other Non-Current Assets rose 1.84% year-over-year to $387000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $387000.0 (up 1.84% YoY) and the FY2025 annual result came in at $395000.0, up 4.5% from the prior year.
• Other Non-Current Assets eased to $387000.0 in Q1 2026 per MREO's latest filing, from $395000.0 in the prior quarter.
• Over the last five years, Other Non-Current Assets for MREO reached as high as $615000.0 in Q4 2023 and fell as low as $378000.0 in Q4 2024.
• A 4-year average of $429222.2 and a median of $395000.0 in 2025 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2024 — Other Non-Current Assets tumbled 38.54% — and 2025, when it grew 4.5%.
• Year by year, Other Non-Current Assets stood at $615000.0 in 2023, then slumped by 38.54% to $378000.0 in 2024, then grew by 4.5% to $395000.0 in 2025, then declined by 2.03% to $387000.0 in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $387000.0, $395000.0, and $394000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.